Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    TopAbstracts in Depression 11/25/2009 - (DGNews)
    Telephone-Delivered Collaborative Care for Treating Post-CABG Depression: A Randomized Controlled Trial - (JAMA)
    TopAbstracts in Depression 11/18/2009 - (DGNews)
    TopAbstracts in Depression 11/11/2009 - (DGNews)
    Evaluating the causal relevance of diverse risk markers: horizontal systematic review - (BMJ)

    News archive

     Recent webcasts/CME - Depression
    • Applying Evidence to Practice in Major Depressive Disorder: An Interactive Panel Discussion
    • Practical Considerations for Front-Line Therapy in MDD
    • Improving Outcomes and Overcoming Barriers in Treatment-Refractory MDD: Practical Strategies and Insights
    • PreAnesthetic Assessment Undergoing Electroconvulsive Therapy
      Antidepressant-Induced Suicidality: Implications for Clinical Practice

      Webcasts/CME archive

       Recent cases - Depression
        Electroconvulsive Therapy-Induced Mania: A Case Report
        Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
        Sexual Dysfunction in a Young Mother
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report

        Cases archive
          




        my personal edition > depression > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Docosahexaenoic Acid, An Omega-3 Fatty Acid, Not Effective In Treating Major Depression

        A DGReview of :"A double-blind, placebo-controlled study of the omega-3 Fatty Acid docosahexaenoic Acid in the treatment of major depression"
        American Journal of Psychiatry

        05/20/2003
        By Emma Hitt, PhD


        Monotherapy with the omega-3 fatty acid docosahexaenoic acid (DHA) does not appear to improve symptoms of unipolar major depression, according to the findings of the first randomised trial evaluating DHA alone.

        Previous studies have suggested that omega-3 fatty acids, found in fish oil, may improve depressive symptoms. The family of omega-3 fatty acids includes eicosapentaenoic acid (EPA) and DHA, but it is unknown whether these agents differ in their ability to influence depression or whether one is more effective than the other.

        Lauren B. Marangell, MD, and colleagues with the Baylor College of Medicine, Houston, Texas, United States, randomised 36 patients to receive DHA, 2 g daily, or placebo for 6 weeks. Patients were between 18 to 65 years of age and met the DSM-IV criteria for major depressive disorder without psychotic features.

        Response was defined as a 50% or more reduction in score on the Montgomery-Asberg Depression Rating Scale. Of the 35 evaluable participants, 18 received DHA, and 17 received placebo.

        The researchers reported that 27.8% in the DHA group qualified as responders compared to 23.5% in the placebo group. The difference in response rates between groups did not reach statistical significance.

        Side effects in the DHA group included a "fish" aftertaste (n=14), belching (n =3), lightheadedness or dizziness (n =3), loose stools (n =2), headache (n =2), and insomnia (n =1). In the placebo group, reported side effects included fatigue (n =3), insomnia (n =1), and loose stools (n =1).

        "Despite the lack of therapeutic response in this study, it is important to note that the rationale for the use of omega-3 fatty acids (both DHA and EPA) in the treatment of bipolar disorder is different from that in unipolar depression," Marangell and colleagues point out.

        "Clearly, more studies are needed to establish the potential role for omega-3 fatty acids in the treatment of affective disorders," they add.
        Am J Psychiatry 2003 May;160:5:996-8. "A double-blind, placebo-controlled study of the omega-3 Fatty Acid docosahexaenoic Acid in the treatment of major depression"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send